Ajinomoto Bio-Pharma Services offers comprehensive capabilities for small molecule APIs and biologics production, from process development and cGMP manufacturing to aseptic fill finish, including cytotoxics. As a global CDMO, we provide the adaptive solutions, responsive service, trusted partnership and peace of mind you’ve come to rely on. [Read More]
BSP Pharmaceuticals is a Contract Development and Manufacturing Organization fully dedicated to antineoplastic drugs, designed to handle the complexity of biopharmaceutical products and offering customized services to support its client from development to commercial manufacturing of injectables and oral formulations. [Read More]
BTI GmbH was founded in 2013 as a linkage between academia and industry. With the vision to provide a robust and versatile enzyme-based conjugation platform BTI developed its novel TrypCo® technology enabling efficient N- or C-terminal modification of basically any protein with a virtually unlimited variety of artificial functionalities like fluorescent probes, toxins or polymers. TrypCo® features a fast and efficient one-step labeling procedure under mild reaction conditions without the need of co-factors or special agents. This highlights TrypCo® as an ideal tool for the generation of site-specifically conjugated ADC´s. www.trypco.de
CARBOGEN AMCIS combines world-class chemistry skills to provide seamless drug development and commercialization services for pharmaceutical and biotechnology companies. Through our customized offering we provide an array of integrated process research and manufacturing services to support the fast supply of complex Antibody Drug Conjugates (ADCs). Our infrastructure is fully cGMP compliant and includes a clean room dedicated to ADCs in Switzerland and a formulation site with lyophilization capabilities in France.
Heidelberg Pharma GmbH is a pharmaceutical company with a dual business model: (A) Providing preclinical drug development services in general with a special focus on the development of ADCs. Heidelberg Pharma has ample experience in providing antibody-drug conjugate related services to its clients. (B) Development of novel therapeutics in oncology based on its own proprietary 2nd generation ADC technology based on a novel toxin.
For over 25 years, Lonza has been helping emerging biotech and pharmaceutical companies improve and advance their products. Whether you are in the early stages of clinical development or providing commercial product to patients around the globe, Lonza supplies complete development services, industry-leading manufacturing, and broad technology platforms that enable products to reach their full potential… Read More
MabPlex International provides one-stop, high-quality CRO/CMO solutions for biologics (mAb and ADCs) to our global clients. We are dedicated to help our clients accelerate development process and reduce manufacture costs. MabPlex has extensive experiences in manufacturing for therapeutic antibodies and antibody-drug conjugates (ADCs). Our manufacturing facilities with large-scale disposable lines and world-class instruments are operated by well-trained professionals in full compliance with U.S, European, and Chinese GMP regulations.
Merck, a leading science and technology company in life science, helps customers advance production capabilities while increasing access to therapies for people worldwide. The development of an ADC requires expertise in small and large molecule handling, manufacturing, formulation and testing. Choosing an experienced partner, with these skills and the required containment facilities can help advance your ADC to market. Whether you are seeking to build your process based on our tailored technology platforms, a service provider – or a combination of both, we can collaborate with you. www.MerckMillipore.com/adcservices